Proteomics International Laboratories (ASX:PIQ) Days Sales Outstanding : 114.23 (As of Jun. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Proteomics International Laboratories Days Sales Outstanding?

Proteomics International Laboratories's average Accounts Receivable for the six months ended in Jun. 2024 was A$0.17 Mil. Proteomics International Laboratories's Revenue for the six months ended in Jun. 2024 was A$0.27 Mil. Hence, Proteomics International Laboratories's Days Sales Outstanding for the six months ended in Jun. 2024 was 114.23.

The historical rank and industry rank for Proteomics International Laboratories's Days Sales Outstanding or its related term are showing as below:

ASX:PIQ' s Days Sales Outstanding Range Over the Past 10 Years
Min: 57.85 Med: 104.02 Max: 142
Current: 64.52

During the past 10 years, Proteomics International Laboratories's highest Days Sales Outstanding was 142.00. The lowest was 57.85. And the median was 104.02.

ASX:PIQ's Days Sales Outstanding is ranked better than
55.88% of 868 companies
in the Biotechnology industry
Industry Median: 70.705 vs ASX:PIQ: 64.52

Proteomics International Laboratories's Days Sales Outstanding increased from Jun. 2023 (0.00) to Jun. 2024 (114.23).

Proteomics International Laboratories Days Sales Outstanding Historical Data

The historical data trend for Proteomics International Laboratories's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Proteomics International Laboratories Days Sales Outstanding Chart

Proteomics International Laboratories Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Days Sales Outstanding

Get a 7-Day Free Trial

101.83

106.21

106.88

142.00

64.24

Proteomics International Laboratories Semi-Annual Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Days Sales Outstanding	Get a 7-Day Free Trial														71.44	82.92	-	42.67	114.23

Competitive Comparison of Proteomics International Laboratories's Days Sales Outstanding

For the Biotechnology subindustry, Proteomics International Laboratories's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Proteomics International Laboratories's Days Sales Outstanding Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Proteomics International Laboratories's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where Proteomics International Laboratories's Days Sales Outstanding falls into.

Proteomics International Laboratories Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

Proteomics International Laboratories's Days Sales Outstanding for the fiscal year that ended in Jun. 2024 is calculated as

	Days Sales Outstanding (A: Jun. 2024 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Jun. 2023 )	+	Accounts Receivable (A: Jun. 2024 ))	/	count )	/	Revenue (A: Jun. 2024 )	*	Days in Period
=	( (0.13	+	0.184)	/	2 )	/	0.892	*	365
=	0.157					/	0.892	*	365
=	64.24

Proteomics International Laboratories's Days Sales Outstanding for the quarter that ended in Jun. 2024 is calculated as:

	Days Sales Outstanding (Q: Jun. 2024 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Dec. 2023 )	+	Accounts Receivable (A: Jun. 2024 ))	/	count )	/	Revenue (A: Jun. 2024 )	*	Days in Period
=	( (0.159	+	0.184)	/	2 )	/	0.274	*	365 / 2
=	0.1715					/	0.274	*	365 / 2
=	114.23

Proteomics International Laboratories (ASX:PIQ) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.

Proteomics International Laboratories Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of Proteomics International Laboratories's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.

Proteomics International Laboratories Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Proteomics International Laboratories Ltd (ASX:PIQ) » Definitions » Days Sales Outstanding

Comparable Companies

Traded in Other Exchanges

N/A

Address

6 Verdun Street, QEII Medical Centre, QQ Block, Nedlands, Perth, WA, AUS, 6009

Website

https://www.proteomics.com.au

Proteomics International Laboratories Ltd is a biological research and drug discovery company. The company specializes in the area of proteomics which is the industrial-scale study of the structure and function of proteins. Its operations are divided into PromarkerD which targets the diabetes epidemic and is a predictive diagnostic test for diabetic kidney disease, a progressive disorder found in one in three adults with diabetes; its proprietary biomarker discovery platform called Promarker, which searches for protein fingerprints in a sample; and Analytical Services that are specialist contract research focusing on biosimilars quality control and pharmacokinetic testing for clinical trials.

Proteomics International Laboratories Headlines

No Headlines